Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2021

View Archived Issues

Triumvira initiates phase I/II trial of TAC-01-HER2 in relapsed or refractory solid tumors

First-in-human trial evaluates RPTR-168 in HPV-16 E6/E7-positive tumors and melanoma

AbCellera and Eli Lilly present second antibody to enter clinical development against COVID-19

First-in-human data for RZ-402 show potential for once-daily dosing

Vivace advances phase I trial of VT-3989 in solid tumors

Seqirus quadrivalent influenza vaccine Flucelvax noninferior to standard in children

Oral oncolytic reovirus RC-402 elicits potent immune responses against colon cancer

Novel GLUT5 inhibitor molecule to treat fructose-induced diseases

Study identifies four Alzheimer's subtypes

Silverback Therapeutics patents TGFBR1 inhibitors

Boswellic acid derivative inhibits Th17 cell differentiation by targeting eIF2alpha

Combination of pacritinib/sirolimus/low-dose tacrolimus for GvHD: preclinical and phase I results

Pipeline Therapeutics synthesizes muscarinic M1 receptor antagonists

BioCryst Pharmaceuticals patent details complement factor D inhibitors

Boehringer Ingelheim discovers TRPA1 antagonists

General Regeneratives patents IL-33 protein for cancer immunotherapy

FDA grants accelerated approval to Keytruda for first-line gastric or GEJ adenocarcinoma

Adagio initiates global phase II/III EVADE study of ADG-20 for the prevention of COVID-19

GB-1265: a galactin-3 inhibitor for corneal fibrosis

Revelation reports phase I data on REVTx-99

ADG-126, a novel cancer immunotherapy candidate with improved safety and efficacy

European Commission approves Xtandi for metastatic hormone-sensitive prostate cancer

Benlysta approved in E.U. for active lupus nephritis

Targeting RRM2 and mutant p53 as novel therapeutic strategy in TNBC

Moderna reports initial COVID-19 vaccine booster data with mRNA-1273 and mRNA-1273.351

Phase II trial evaluates Telomelysin, pembrolizumab and stereotactic radiation in head & neck cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...